CD8A and hepatocellular carcinoma: As cytokine support, short courses or locoregional dosing of IL-15, including engineered hyper-IL-15, can expand CD8+ effectors and boost their function, with antitumor activity reported in liver metastasis and spontaneous HCC models, suggesting compatibility with ICI therapy or cell-based treatments (137, 138).